OA16586A - Hemisphere for bladder expansion in patents with low compliance. - Google Patents

Hemisphere for bladder expansion in patents with low compliance. Download PDF

Info

Publication number
OA16586A
OA16586A OA1201300373 OA16586A OA 16586 A OA16586 A OA 16586A OA 1201300373 OA1201300373 OA 1201300373 OA 16586 A OA16586 A OA 16586A
Authority
OA
OAPI
Prior art keywords
hemisphere
implant
bladder
carbon
cells
Prior art date
Application number
OA1201300373
Inventor
Antonio Sambusseti
Original Assignee
Antonio Sambusseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antonio Sambusseti filed Critical Antonio Sambusseti
Publication of OA16586A publication Critical patent/OA16586A/en

Links

Abstract

A description is given of a device for the expansion of an atrophied bladder formed by a hemisphere (100, 200), as a single piece, in biocompatible material characterised in that said material is selected from polylactic acid (PLA) and silicone coated with pyrolytic turbostratic carbon or with amorphous diamond-like carbon.

Description

The présent invention relates to a hemisphere for bladder expansion in patients with low compliance (low filling capacity) in the treatment and therapy of atrophied bladders.
Patients with low compliance generally hâve an atrophied bladder whose volume is about 150200 cc, i.e. much smaller than the volume of a healthy bladder which is normally around 400 cc. This entails, as is intuitive, serious problems for the patient.
In bladder expansion surgical procedures the replacement of the atrophied bladder with an artificial bladder, for example the one described in W02009/077047, is a method generally not practised since the tissue of the atrophied bladder is not considered a damaged tissue.
In fact, in order to increase the available volume of an atrophied bladder use is normally made of a prosthesis with a hemisphere shape to be sutured on the incised atrophied bladder.
This hemisphere is made with the tissue of the intestine of the actual patient in order to hâve high compatibility and reduced rejection with reduced formation of the fîbrous capsule.
However the tissue of the intestine does not always hâve the mechanical properties of the bladder such as elasticity, or the ability to assume stably a substantially hemisphere shape necessary for expansion of the bladder.
The patent application WO 2007/095193 describes an implant made up of a hemisphere covered by a population of cultivated, autologous or allogeneic cells, suitable for reconstructing, in a genetic laboratory, the three-dîmensional structure of the tissue or of the organ which is then to be implanted in the patient The hemisphere is therefore used as a support for depositing on its surface a population of cells cultivated in vitro.
This implant, which is only implanted after having been covered with cells, is somewhat complex, costly and lengthy to produce seeing that before the phase of covering with cells it is necessary to carry out a sériés of lengthy and complex preparatory phases: an initial phase of isolation of the cells to be cultivated by means of biopsy, a phase of growing of the isolated cell number, one of population as well as a phase of pre-treatment of the surface of the hemisphere so that it can be populated by the cells.
Moreover the aforesaid hemisphere has to provide fins, rings and handpieces necessary for a manipulation by the surgeon without damage to the tissue placed over it, thus making the construction of this hemisphere more complex.
Implants are also known with a planar or slightly curved shape suitable for the replacement of portions of bladder wall such as for example the patch described in WO 2007/039160 and the scaffold described in WO 2011/018300, which however, given their shape, cannot be used for bladder expansion in that they cannot be transformed into devices endowed with volume.
The object of the présent invention is to eliminate, at least in part, the disadvantages of the prior art, by providing a device (implant) for bladder expansion in patients with low compliance, which is elastic but also with such rigidity as to be able to maintain the rounded shape of the bladder, once implanted, which is reliable without showing possible leaks of liquid and which is résistant to urine.
Another object of the présent invention is to provide such a device which is also with zéro rejection, with lack of adhérence of the fibrous capsule and provided with high compatibility, which allows tissue reconstruction of similar quality to the original tissue.
Another object of the présent invention is that of providing such a device which is simple and easy to manufacture and can be implanted in the patient without excessive preparatory phases.
These objects are achieved by a biocompatible hemisphere device according to the invention having the features listed in the annexed independent claim 1.
Advantageous embodiments of the invention are disclosed by the dépendent claims.
The device according to the invention for expansion of the atrophied bladder is made up of a domed hemisphere, elastic and flexible and internally hollow, having a predetermined volume, made as a single piece of a biocompatible material which guarantees the absence of fibrous capsule around it once implanted.
The biocompatible material is selected from PLA and silicone coated with pyrolytic turbostratic carbon or with amorphous diamond-like carbon. This hemisphere has smooth internai and external surfaces, even when coated with pyrolytic turbostratic carbon or amorphous diamondlike carbon. Moreover this hemisphere is lacking any covering by cultivated tissue cells and any surface treatment for encouragîng the grafting of the growing tissues. In practice the aforesaid hémisphère is suitable for acting as scaffold only after insertion inside the patient, and for causing to grow on it only autologous cells from fibrous capsule, generated by the process of tissue reconstruction of the patient, which only takes place after its insertion.
Said hémisphère may hâve a plurality of holes, equally distanced and positioned on its perimeter rim projecting outwards (by way of a flange) in order to pass the suture thread through which is to fix said hemisphere to the non-removed bladder part.
The hemisphere shape of this device is imparted during the process of production of the same by means of moulding, during production and not during the operation phase.
Further features of the invention will be made clearer by the following detailed description, referred to one of its embodiments purely by way of a non-limiting example illustrated in the accompanying drawings, in which:
Fig. 1 is a perspective view of a bladder with low compliance with relative ureters and urethra; Fig. 2 is a perspective view of the bladder of Fig. 1 wherein the upper part has been eut in order to be replaced by a hemisphere of the invention;
Fig. 3 a) is a plan view from below of the hemisphere according to a first embodiment of the invention;
Fig. 3 b) is a sectioned view of the hemisphere of Fig. 1 a) taken along line l-l;
Fig. 4 a) is a view from below of the hemisphere according to a second embodiment of the invention;
Fig. 4 b) is a sectioned view of the hemisphere of Fig. 2 a) taken along line ll-ll;
Figs. 5 a)-b) are perspective views of the atrophied bladder in the phases of expansion by insertion of the hemisphere.
Referring to Figures 3-4 (a, b) indicated above, a hemisphere according to the invention is described, denoted overall by reference numéral 100.
The hemisphere 100 is internally hollow, has a circular profile in a plan view with diameter of about 80 mm and has a rim 1 projecting outwards and turned upwards.
In this first embodiment said hemisphere 100 is made of a biocompatible polymer which is also absorbable, constituted by the homopolymer or copolymers with base of lactic acid (L-, D-, racemic mixture, or dimer, esters, etc. or combinations thereof).
Particularly preferred is poly(D-lactide) acid or the poly(L-lactîde-co-D,L-lactide) copolymer
polyester (PLDLA, or otherwise identified also as PLDL or PLLA/PDLLA). This polyester is a copolymer having an L-lactide:D,L-lactide monomer composition of about 70:30. It is also possible to use a PLDLA copolymer as defined above, having a different monomer composition, for example with a monomer content of the L-lactide comonomer comprised between 70% and 30% (the D,L-lactide comonomer is the complementary part to 100).
Another example of polymer which can be used is poly-L-D-lactide acid, preferably having an Llactide:D-lactide monomer composition of 70/30 or 50/50.
The aforesaid polymers with lactic acid base were found to be neutral when in contact with noncultivated cells: this entails a rapid population of the device implanted by the cells of the growing surrounding tissue. At the same time the adhesion was found to be reduced due to the reduced interaction between these polymers and the biological molécules.
The thickness 3 of said hemisphere 100 is not binding for the purpose of the présent invention: it is fairly reduced but is such as to ensure a sufficient rigidity such as to resuit in a selfsupporting hemisphere, ensuring at the same time the elasticity and the flexibility necessary for the movements (dilations) of expansion and collapsing of the bladder due to the filling and emptying of the same.
Said thickness 3 may vary between 0.1 mm and 2 cm. In a preferred embodiment said thickness 3 is around 0.5-0.6 mm when the hemisphere is tn silicone, while it is about 1 mm when it is made in PLA.
On the rim 1 of said hemisphere 100 in polylactic acid there is a plurality of holes 2 whose pitch is not binding for the purpose of the présent invention and dépends on the diameter of the holes 2. The diameter of the holes 2 may vary from a minimum to a maximum comprised between 0.1 and 3.0 mm.
In a preferred embodiment the holes 2 hâve a diameter of about 1 mm and are distanced with a pitch of 2.5 mm.
Said hemisphere 100 in PLA is obtained by means of moulding, even if it is possible to obtain it with other known techniques normally used for the formation of concave and hollow objects, formed in a single piece in a polymeric material.
In Figs. 4a, 4b a second embodiment of the hemisphere in accordance with the invention is illustrated, denoted by the reference numéral 200.
Said hémisphère 200 has substantially the same diameter (or radius of the sphere) of the hémisphère 100, the same rim 1 turned upwards, yet it is made in silicone coated internally and externally with pyrolytic turbostratic carbon or amorphous diamond-like carbon (DLC).
Amorphous diamond-like carbon is a carbon coating, white or transparent, with stratified structure similar to the diamond (defined in fact as diamond-like carbon) with outstanding features of surface résistance such as hardness and résistance to abrasions, as weli as being well tolerated by the skin and résistant to corrosion yet elastic.
Moreover it is neutral when in contact with cells and micro-organisms: this entails a rapid population of the device implanted by the cells of the growing surrounding tissue. At the same time the adhesion is reduced due to the reduced interaction between the coated surface and the biological molécules.
This coating of amorphous diamond-like carbon can also be “doped” with various compounds to achieve oil repellency or water repellency.
The coating in pyrolytic turbostratic carbon also has features of surface résistance, résistance to abrasions, résistance to corrosion. Moreover said pyrolytic turbostratic carbon was also found to be neutral when in contact with cells, resulting in a rapid population of the device implanted by the cells of the growing surrounding tissue.
At the same time the adhesion of the pyrolytic turbostratic carbon to the tissues is almost totally absent due to the reduced interaction between the coated surface and the biological molécules. In this way a substantial absence is obtained of the phenomenon of fusion to the surrounding tissues which takes place instead when other materiais are used, for example a membrane of only silicone.
The silicone in fact has the tendency to co-penetrate with the polyprotein fibrous growth (red blood cells) and to fuse with the neotissues.
The tissues which are reconstructed around the present device, whether in PI_A or in coated silicone, are moreover of similar quality to the original tissue, in particular they show substantially the same original elasticity.
The silicone used can be made up, for example, of copolymers of dimethyl and metavinyl siloxane, reinforced with silicon. A silicone for medical use is preferably used, such as for example that known by the code MED 4735™ and marketed by the company Nusil Technology.
Preferably said hemisphere 200 in coated silicone does not have holes 2 along the rim 1 since 5 they can be made at the time of the suture of the hemisphere 200 being very elastic.
In practice the layer of silicone which constitutes the hemisphere 200 is formed by a membrane provided with sufficient flexibility, so as to ensure the proper functioning of the bladder.
The thickness 4 of said hemisphere 200 in silicone is preferably about 600 microns.
The thickness of the layer of coating 5 in pyrolytic turbostratic carbon or in amorphous diamond-like carbon is not binding for the purpose of the présent invention and can be for example a microfilm of approximately 0.2 - 0.3 micron.
The application of said layer 5 of pyrolytic turbostratic carbon or of amorphous diamond-like carbon (DLC) is performed according to a known technique, such as for example PVD in the case of DLC.
The hemisphere 100,200 is prepared in a controlled environment that is to say with controlled contamination, in a white room. Once processing has finished, the hemisphere 100,200 is enclosed by a sheet of Tyvek to avoid contaminations, and sent to a cycle of stérilisation with base of ETO (ethylene oxide) or sent to a cycle of stérilisation with gamma rays (in the case of PLA). At this point the hemisphere is ready to be used in an operation.
The hemisphere 100, 200, without any covering with cultured cells, is applied to the bladder in place of the part removed according to known surgical techniques, after having sectioned the bladder and removed the upper portion, leaving the connections of the urethra and ureters to this bladder intact.
In fact the atrophied bladder 300 (Fig. 1) can be first eut into two parts, the upper part 21 whereof (Fig. 2) is removed while around the perimeter of the lower part 22 not removed the hemisphere 100 or 200 is sutured.
Alternatively, as illustrated in Figs. 5a) and 5b), the atrophied bladder 300, comprising ureters 35 and urethra, is only încised with a cross eut, opened and subsequently sutured to the hemisphere 100, 200 around the rim of the opening created by the eut. Over this hemisphere the neotissue will then form that cornes from the natural growth of the polyprotein capsule around this implanted hémisphère, and therefore not coming from cultured cells.
For each of the embodiments of the hemisphere 100, 200 described above, suture threads in absorbable or non-absorbable material can be used for the through suture.
In the case of the hemisphere in silicone coated with pyrolytic turbostratic carbon or amorphous diamond-like carbon, it is préférable to use absorbable thread in order to be able to remove easily the hemisphere 200 after a certain period, in general after 30 days, via simple withdrawal of the same from a side by means of removal in laparoscopy, or by removal in endoscopy, performed in day hospital or day surgery or day hospital with an operation, also without anaesthetic, lasting a few minutes.
In fact after the 30 days the hemisphere in coated silicone has to be removed in that at the end of the process of reconstruction of the bladder it falls inside it after the fixing suture, made with absorbable thread, has been absorbed.
The suture thread for the hemisphere 100 in PLA is also preferabiy in absorbable material, for example like the polymers mentioned above for the hemisphere 100 of the présent invention, preferabiy PLA, PLLA. The reasons for this choice lie in the need for the hemisphere and sutures to be absorbed in the same timespan. The suture thread is then inserted in a round % curved cylindrical needle, including the “Bassini ones.
Other suture threads in bio-absorbable polymers in any case exist which could be conveniently adapted to the case in question and to the needs at the discrétion of the surgeon.
However in the case of the hemisphere 100 in PLA the choice of the material of the suture thread is less important given the absorbability of the PLA after the 30 days.
The holes 2 for passage of the suture stitches do not constitute a risk of leaks of liquid, in that the tissue is reconstructed in a few hours. To avoid leaks of urine (liquid), the holes of the suture stitches can be sealed and closed with one cc (a drop) of surgical glue, such as for example Glubran 2™, normally available commercially.
One of the advantages of the hemisphere 100, 200 of the présent invention is that it does not show any risk of adhérence of the fibrous capsule both thanks to the coating in pyrolytic turbostratic carbon or amorphous diamond-like carbon which do not show any adhérence with the growing tissues and to the absorbability of the PLA.
Moreover the hémisphères 100, 200 are résistant to urine and, in the case of the silicone, also considerably elastic.
Another advantage is represented by the fact that the présent hemisphere can be used as an implant in the patient even without prior covering of its surface with cells cultivated in vitro, contrarily to what is taught by W02007/095193, in light of the fact that the présent hemisphere îs able to act as a scaffold only after having been implanted inside the patient, causing to grow thereon only autologous cells from fibrous capsule, generated by the process of tissue reaction and reconstruction of the organism.
This entails a conséquent saving in time and costs due to the non-use of machinery, apparatuses and staff highly qualified in genetics, tissue engineering and biology seeing that the cultured cells can corne either from the patient or from a donor and be xenogeneic cells, or mixed, and that therefore these cells have to be obligatorily treated with immunodepressive therapy to make them compatible with the receiver.
It also has to be noted that in the art, for example in W02007/095193, the neotissue or neobladder is made in a laboratory, under a hood, using the cultures positioned on the one or on the two hémisphères, including urethra and ureters, and that this neotissue or neobladder is implanted in the patient, removing the bladder completely, suturing urethra and ureters, and therefore the neobladder, or part thereof, does not have to form inside the patient in that it is already made in the laboratory, with cultured cells. In practice, seeing that the neobladder is already made when it is implanted, there is not tissue growth over these scaffolds of the prior art but only their absorption and the intégration of the neobladder inside the patient.
Numerous detail modifications and changes, within the reach of a person skilled in the art, may be made to the présent embodiments of the invention, in any case coming within the scope of the invention disclosed by the annexed claims.

Claims (7)

1. Implant for increasing the volume of an atrophied bladder, said implant being constituted by a domed hemisphere device (100,200), internally hollow with a predetermined volume, made in a single piece in biocompatible material, the internai and external surfaces of said hemisphere are without covering from semination of cultured cells, characterised in that said material is silicone coated with pyrolytic turbostratic carbon or with amorphous diamond-like carbon, and in that said hemisphere is suitable for acting as a scaffold and for growing thereon autologous cells from fibrous capsule, generated by the process of tissue reconstruction of the patient, after its insertion inside the patient.
2. Implant (100, 200) according to claim 1 wherein the diameter of the hemisphere is about 80 mm.
3. Implant (100, 200) according to claim 1 or 2 wherein the hemisphere has a rim (1) turned upwards.
4. Implant (100, 200) according to any one of the previous claims wherein the hemisphere has a thickness (3;4) ranging from 0.1 mm to 2 cm, preferably about 0.5-0.6 mm.
5. Implant (100) according to claim 4 wherein the hemisphere has on the rim (1) a plurality of holes (2), preferably with a diameter of the holes comprised between 0.1 and 3.0 mm.
6. Implant (200) according to any one of the previous claims 1-5 wherein the coating (5) of pyrolytic turbostratic carbon or amorphous diamond-like carbon is a microfilm of about 0.2 - 0.3 micron.
7. Implant (100, 200) according to any one of the previous claims wherein the suture thereof to the bladder is performed by using suture threads made of absorbable or non-absorbable material, preferably with absorbable thread.
OA1201300373 2011-03-11 2012-03-02 Hemisphere for bladder expansion in patents with low compliance. OA16586A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2011A000387 2011-03-11

Publications (1)

Publication Number Publication Date
OA16586A true OA16586A (en) 2015-11-20

Family

ID=

Similar Documents

Publication Publication Date Title
JP6113202B2 (en) Dilated bladder expansion prosthesis
US20120226352A1 (en) Self supporting and forming breast implant and method for forming and supporting an implant in a human body
BR122023022068A2 (en) IMPLANTABLE PROSTHESIS COMPRISING A BODY OF BIOCOMPATIBLE MATERIAL
US9017378B2 (en) Surgical thread comprising cells and method of manufacturing the thread
AU2012228495B2 (en) Hemisphere for bladder expansion in patients with low compliance
EA028683B1 (en) Material for implantation (embodiments), dental implant, vascular implant and tissue implant for a soft tissue replacement plasty
EP3248565A1 (en) Pocket-type membrane for implant procedure
OA16586A (en) Hemisphere for bladder expansion in patents with low compliance.
US9248012B2 (en) Mesh based fluid delivery prosthesis and method of use
RU2696877C2 (en) Absorbable and biocompatible graft for prosthetic implantation after excising ipp plaque
JP2021500214A (en) Reticular formation multi-cell dual system ocular implant
AU2014336244B2 (en) PGA tubular patch and relative optional tubular support made of absorbable material for the tissue reconstruction of urethral and/or ureteral removed segments
CN117065096B (en) Rapid preparation method and application of biological film
RU2269308C1 (en) Method for testicular prosthetics at monorchism and anorchism
CN106834222A (en) A kind of method for cultivating Bone flaps with vascular pedicle
CN117018283A (en) Multi-layer nano-fiber artificial dura mater using polyaryletherketone as substrate and preparation method thereof
Rau Approaches and Impacts of Replacement, Reconstruction, and Regeneration in Medical Applications
OA17687A (en) PGA tubular patch and relative optional tubular support made of absorbable material for the tissue reconstruction of urethral and/or ureteral removed segments.
JPWO2019083350A5 (en)